Affinity Asset Advisors, LLC Mirati Therapeutics, Inc. Transaction History

Affinity Asset Advisors, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	BUY	$41.99 - $62.38 $1.66 Million - $2.47 Million	39,623 Added 65.57%	100,049 $5.88 Million
Q3 2023 Nov 14, 2023	BUY	$27.8 - $45.35 $1.68 Million - $2.74 Million	60,426 New	60,426 $2.63 Million
Q1 2022 May 13, 2022	SELL	$75.82 - $150.97 $1.52 Million - $3.02 Million	-20,000 Closed	0 $0
Q4 2021 Feb 11, 2022	SELL	$132.01 - $190.29 $990,074 - $1.43 Million	-7,500 Reduced 27.27%	20,000 $2.93 Million
Q3 2021 Nov 12, 2021	BUY	$132.13 - $177.45 $3.63 Million - $4.88 Million	27,500 New	27,500 $4.87 Million

Q1 2021 May 14, 2021	SELL	$158.92 - $221.61 $1.59 Million - $2.22 Million	-10,000 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$162.05 - $240.27 $1.62 Million - $2.4 Million	10,000 New	10,000 $2.2 Million

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Affinity Asset Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Affinity Asset Advisors, LLC with notifications on news.